GSK falls in line with Big Phar­ma's re­ac­tion to Ukraine in­va­sion, cut­ting off new clin­i­cal tri­als, do­nat­ing prof­its and more

Just a few days af­ter mul­ti­ple Big Phar­mas such as Bay­er and Pfiz­er start­ed the de-fac­to Big Phar­ma re­sponse to Russ­ian ag­gres­sion in Ukraine, oth­er glob­al play­ers such as No­var­tis and Eli Lil­ly start­ed to fol­low suit, push­ing be­yond its first ten­ta­tive steps with a full-throat­ed com­mit­ment to sev­er­ing busi­ness ties with Rus­sia wher­ev­er pos­si­ble.

Now an­oth­er one of the hand­ful of hold­outs is pil­ing on: Lon­don-based Glax­o­SmithK­line. The phar­ma — helmed by Em­ma Walm­s­ley — an­nounced overnight that the com­pa­ny has tak­en a few ac­tions in Rus­sia, say­ing:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER